Source disclosure: February 18, 2026
CanBas Co.,Ltd. [4575.T]
TOKYO, Feb 18 (Pulse News Wire) – Canbas CO.,LTD. (4575.T) reported a lower net profit of ¥--¥568 million for the quarter ending June 2026, compared ¥88 million in the same period last year.
The losses were primarily attributed to ongoing clinical development investments for its lead compound, CBP501, which includes expenses related to preparing for the European Phase III trial application. The company's research and development expenditure reached -¥600 million, with ¥339 million allocated specifically towards CBP501’s European Phase III trial preparation costs. Additionally, administrative and general expenses amounted to ¥155 million. Operating income stood at a loss of ¥--¥600 million, while ordinary income was also negative at ¥--¥568 million.
In positive developments, CanBas recently concluded a licensing agreement with Stemline Therapeutics, returning all rights associated with the CBS9,106 license. The company now plans to conduct foundational research to develop a concrete clinical development plan post-return procedures. Looking ahead, CanBas remains focused on advancing CBP501 through its European Phase III trials despite uncertainties surrounding the timing and conditions of approval. The company continues to monitor potential risks and adjust strategies accordingly to ensure adequate funding for future phases of the trial.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing